Literature DB >> 8109727

An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation.

A Kawaji1, K Ohara, E Takabatake.   

Abstract

An assay system of flavin-containing monooxygenase was developed by fluorometric determination of benzydamine (BZY) N-oxidation with HPLC. The apparent Km value for the formation of BZY N-oxide from BZY by rat liver microsomes was similar to that by purified FMO. The Km and Vmax values for the formation of N-desmethylbenzydamine (Nor-BZY) by rat liver microsomes were about 50 times greater and 2000 times less, respectively, than those of BZY N-oxide. Nor-BZY was not formed upon incubation with purified enzyme. BZY N-oxidation activity was completely inhibited both in the absence of NADPH and by heat inactivation. The reaction was inhibited in the presence of 0.5 mM thiourea, but 2 mM SKF-525A did not affect BZY N-oxidation. Moreover, rabbit antibody raised against the rat enzyme inhibited BZY N-oxidation. These results are in accord with a simple, rapid, and sensitive assay for the enzyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109727     DOI: 10.1006/abio.1993.1515

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  3 in total

1.  Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.

Authors:  E Störmer; I Roots; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.

Authors:  Catherine K Yeung; Elinor T Adman; Allan E Rettie
Journal:  Arch Biochem Biophys       Date:  2007-05-02       Impact factor: 4.013

3.  Pulmonary Metabolism of Substrates for Key Drug-Metabolizing Enzymes by Human Alveolar Type II Cells, Human and Rat Lung Microsomes, and the Isolated Perfused Rat Lung Model.

Authors:  Katarina Rubin; Pär Ewing; Erica Bäckström; Anna Abrahamsson; Britta Bonn; Satoshi Kamata; Ken Grime
Journal:  Pharmaceutics       Date:  2020-02-01       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.